- Home
- PRLD
as 01-17-2025 4:00pm EST
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 73.7M | IPO Year: | 2020 |
| Target Price: | $4.50 | AVG Volume (30 days): | 611.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $6.80 | Next Earning Date: | 02-13-2025 |
| Revenue: | $3,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Prelude Therapeutics Incorporated (PRLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vaddi Krishna | PRLD | CEO | Dec 31 '24 | Buy | $1.21 | 5,000 | $6,043.50 | 142,553 | |
| Vaddi Krishna | PRLD | CEO | Dec 30 '24 | Buy | $1.20 | 10,000 | $12,000.00 | 142,553 | |
| Combs Andrew | PRLD | Chief Chemistry Officer | Dec 20 '24 | Buy | $1.26 | 63,075 | $85,538.25 | 317,623 | |
| Lim Bryant David | PRLD | CLO, Interim CFO, Corp Sec. | Dec 19 '24 | Buy | $0.91 | 25,000 | $22,637.50 | 27,400 | |
| Vaddi Krishna | PRLD | CEO | Dec 18 '24 | Buy | $0.91 | 106,888 | $99,325.86 | 142,553 |
Latest Prelude Therapeutics Incorporated News
PRLD Breaking Stock News: Dive into PRLD Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics
TipRanks
a month ago
Prelude Therapeutics presents first interim data from trial of PRT2527
GlobeNewswire
a month ago
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Simply Wall St.
2 months ago
November 2024's Top Picks: Penny Stocks On US Exchanges
Zacks
2 months ago
After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)
GlobeNewswire
2 months ago
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Zacks
2 months ago
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD)
GlobeNewswire
2 months ago
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Compare PRLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRLD Prelude Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.